Clinical Efficacy and Safety Profile of Micropulse Transscleral Cyclophotocoagulation in Refractory Glaucoma

2018 ◽  
Vol 27 (5) ◽  
pp. 445-449 ◽  
Author(s):  
Alice L. Williams ◽  
Marlene R. Moster ◽  
Kamran Rahmatnejad ◽  
Arthur F. Resende ◽  
Teresa Horan ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Safety Profile ◽  
Efficacy And Safety ◽  
Refractory Glaucoma ◽  
Transscleral Cyclophotocoagulation

scholarly journals Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation

Cureus ◽  
2019 ◽  
Author(s):  
Asim Tameez Ud Din ◽  
Ameer H Khan ◽  
Hamza Bajwa ◽  
Muhammad Haisum Maqsood ◽  
Mustafa N Malik
Keyword(s):  
Clinical Efficacy ◽  
Safety Profile ◽  
Efficacy And Safety ◽  
Idiopathic Constipation ◽  
Chronic Idiopathic Constipation

Clinical efficacy and safety following dose tapering of ciclosporin in cats with hypersensitivity dermatitis

2016 ◽  
Vol 18 (11) ◽  
pp. 898-905 ◽  
Author(s):  
Elizabeth S Roberts ◽  
Tiffany Tapp ◽  
Ann Trimmer ◽  
Linda Roycroft ◽  
Stephen King
Keyword(s):  
Adverse Events ◽  
Clinical Response ◽  
Clinical Efficacy ◽  
Safety Profile ◽  
Therapeutic Response ◽  
Clinical Pathology ◽  
Efficacy And Safety ◽  
Dosing Frequency ◽  
Dosing Regimens ◽  
Physical Examinations

Objectives This study was designed to evaluate the efficacy and safety of reducing ciclosporin (CsA) dosing frequency from daily to every other day (EOD) or twice a week (TW) according to clinical response in cats with hypersensitivity dermatitis (HD) and treated with CsA. Methods One hundred and ninety-one cats with HD were given 7 mg/kg CsA daily for at least 4 weeks. Depending on clinical response, the dosing frequency was tapered from daily to EOD over the next 4 weeks and further to TW for an additional 4 weeks. Safety was evaluated through physical examinations, clinical pathology and the monitoring of adverse events (AEs). Results The majority of cats were able to have their dose of CsA tapered to either EOD (15.5%) or TW (62.9%) according to the clinical response. Observed AEs were most frequently mild and self-limiting vomiting and diarrhea. A higher percentage of AEs occurred with daily administration (73%) compared with other dosing regimens (27%). Conclusions and relevance Following 4 weeks of daily dosing at 7 mg/kg, CsA may be tapered to EOD or TW while maintaining the desired therapeutic response in cats with HD. Additionally, CsA appears to be well tolerated with fewer AEs at EOD or TW dosing. Establishing the lowest effective dosing frequency of CsA improves the drug’s safety profile.

scholarly journals Comparison of Ultrasound Cycloplasty and Transscleral Cyclophotocoagulation for Refractory Glaucoma in Chinese Population

2020 ◽  
Author(s):  
Qiuli Yu ◽  
Ya Liang ◽  
Fangfang Ji ◽  
Zhilan Yuan
Keyword(s):  
Visual Acuity ◽  
Chinese Population ◽  
Baseline Level ◽  
Focused Ultrasound ◽  
Efficacy And Safety ◽  
Refractory Glaucoma ◽  
Corrected Visual Acuity ◽  
Transscleral Cyclophotocoagulation ◽  
Time Point

Abstract Background To compare the efficacy and safety of focused ultrasound cycloplasty (UCP) and transscleral cyclophotocoagulation (TSCP) in the treatment of refractory glaucoma in a Chinese population. Methods We retrospective compared twenty-eight eligible patients with refractory glaucoma, who were divided into the UCP group and TSCP group. Patients in these two groups underwent a corresponding procedure from June 2018 to February 2019. The intraocular pressure (IOP), visual acuity, the number of anti-glaucoma agents used and complications were reviewed and compared between groups. Proper statistical methods were selected according to comparison models under IBM SPSS 25 software. Results After the 12-months follow-up, postoperative IOP and number of anti-glaucoma agents used in the two groups were both reduced than the baseline level, and the differences were statistically significant (P<0.05). There were no significant differences in IOP, number of anti-glaucoma agents and the best-corrected visual acuity between the two groups at each follow-up time point (P＞0.05). In terms of complications, the pain at 1 day after surgery in the UCP group was significantly milder than that in the TSCP group (P<0.05). And there were no significant differences in other complications between the two groups (P>0.05). Conclusions Both UCP and TSCP are safe and effective methods for the treatment of refractory glaucoma. Nevertheless, pain is less severe after UCP.

scholarly journals A RANDOMIZED ACTIVE CONTROLLED CLINICAL STUDY TO EVALUATE EFFICACY AND SAFETY OF RESVERATROL AS AN ADJUVANT THERAPY IN PATIENTS WITH HYPERTENSION

2016 ◽  
Vol 10 (1) ◽  
pp. 376
Author(s):  
Rakesh Ojha ◽  
Kulkarni Pranesh ◽  
Vyas Bhavin
Keyword(s):  
Essential Hypertension ◽  
Adjuvant Therapy ◽  
Clinical Efficacy ◽  
Safety Profile ◽  
Gold Standard ◽  
Standard Therapy ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Hypertensive Patients

ABSTRACTObjectives: No long-term clinical efficacy and safety study of resveratrol as adjuvant therapy along with gold standard therapy has been conductedin patients with essential hypertension. The aim of this study was to investigate the efficacy and safety of resveratrol as an adjuvant therapy in newlydiagnosed hypertensive patients.Methods: In this randomized active-controlled study, hypertensive patients (male/female) of 20-65 years aged were randomized (1:1) to receivetelmisartan 20 mg or telmisartan 20 mg plus resveratrol 1 g daily for 12 months. Efficacy variables included a change in systolic and diastolic bloodpressure (DBP) from baseline and were followed up for every 3 months. Treatment-emergent adverse events were assessed.Results: A total of 60 hypertensive patients were analyzed (telmisartan [n=30] and telmisartan plus resveratrol [n=30]). Resveratrol as an adjuvantwith telmisartan significantly reduced in systolic (p<0.001) and DBP (p<0.001) as compared to telmisartan monotherapy. Change in systolic and DBPfrom baseline was significantly higher in telmisartan plus resveratrol group than telmisartan (p<0.001) at all followed visits. Both the study drugshave similar safety profile and found well tolerable.Conclusions: Resveratrol plus Telmisartan was found to be superior over telmisartan monotherapy in reducing systolic and DBP in newly diagnosedhypertensive patients. Both the study drugs were effective with comparable safety profile. Our study supports the long-term clinical efficacy andsafety study of resveratrol along with gold standard therapy in essential hypertension.Keywords: Essential hypertension, Resveratrol, Systolic and diastolic blood pressure, Telmisartan.

scholarly journals MicroRNA hsa-miR-370-3p is a new biomarker for assessing the level of CYP2D6 gene expression, as well as the clinical efficacy and safety of mirtazapine in patients with depressive disorders comorbid with alcohol use disorder

2020 ◽  
pp. 62-63
Author(s):  
М.С. Застрожин ◽  
В.Ю. Скрябин ◽  
Е.А. Гришина ◽  
К.А. Рыжикова ◽  
И.В. Буре ◽  
...  
Keyword(s):  
Gene Expression ◽  
Plasma Concentration ◽  
Gene Polymorphism ◽  
Clinical Efficacy ◽  
Safety Profile ◽  
Alcohol Use Disorder ◽  
Depressive Disorders ◽  
Polymorphic Marker ◽  
Efficacy And Safety ◽  
Cyp2d6 Gene

Проведено изучение влияния полиморфизма гена CYP2D6 на эффективность и безопасность терапии миртазапина у пациентов с депрессивными расстройствами, коморбидными с алкоголизмом. В группе из 106 пациентов с депрессивными расстройствами, коморбидными с алкогольной зависимостью, было продемонстрировано влияние полиморфизма 1846G>A гена CYP2D6 (rs3892097) на показатели профиля безопасности миртазапина, но не эффективности. При этом hsa-miR-370-3p остается перспективным биомаркером оценки уровня экспресии гена CYP2D6, так как уровень его плазменной концентрации отличался у носителей разных генотипов по полиморфному маркеру 1846G>A, хотя и не обнаружилась связь с клинической эффективностью и безопасностью. The study of the effect of CYP2D6 gene polymorphism on the efficacy and safety of mirtazapine therapy in patients with depressive disorders comorbid with alcoholism was carried out. In a group of 106 patients with depressive disorders comorbid with alcohol dependence, the effect of the 1846G> A polymorphism of the CYP2D6 gene (rs3892097) on the safety profile of mirtazapine was demonstrated, but not on the effectiveness. At the same time, hsa-miR-370-3p remains a promising biomarker for assessing the level of CYP2D6 gene expression, since the level of its plasma concentration differed in carriers of different genotypes for the polymorphic marker 1846G> A, although no connection with clinical efficacy and safety was found.

Sign in / Sign up

Export Citation Format

Share Document